Placental expressions of Anti-Mullerian hormone/Receptor, vascular endothelial growth factor and related microRNAs in patients with preeclampsia: a case control study.

IF 1.6 4区生物学 Q4 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Biotechnic & Histochemistry Pub Date : 2024-08-21 DOI:10.1080/10520295.2024.2389516

Pinar Solmaz Hasdemir, Didem Celikcekic, Mustafa Oztatlici, Kemal Ozbilgin

{"title":"Placental expressions of Anti-Mullerian hormone/Receptor, vascular endothelial growth factor and related microRNAs in patients with preeclampsia: a case control study.","authors":"Pinar Solmaz Hasdemir, Didem Celikcekic, Mustafa Oztatlici, Kemal Ozbilgin","doi":"10.1080/10520295.2024.2389516","DOIUrl":null,"url":null,"abstract":"<p><p>Anti-Mullerian hormone (AMH) has been implicated in the pathogenesis of preeclampsia. The present study was primarily designed to determine the placental tissue AMH, Anti-Mullerian hormone Receptor II (AMHRII), vascular endothelial growth factor (VEGF) and microRNA (miRNA) 26a/126/155/210 expressions and serum miRNA 26a/126/155/210 levels in patients with preeclampsia to examine their potential role in the pathogenesis of preeclampsia. Placental tissue samples from patients with preeclampsia (n = 20) and control subjects (n = 20) were examined by immunohistochemical staining and quantitative polymerase chain reaction (qPCR) for AMH, AMHRII, VEGF mRNA expression levels and miRNA 26a/126/155/210 expressions. Serum levels of miRNA 26a/126/155/210 were measured by qPCR. Patients with preeclampsia had lower AMH/AMHRII immunostaining, particularly in syncytiotrophoblastic cells compared to control subjects (p < 0.05). The relative mRNA expressions of AMH/AMHRII were increased (1.535 ± 0.121 and 1.155 ± 0.049 fold, p < 0.0002 and p < 0.033, respectively) and the relative mRNA expression of VEGF was decreased (4.878 ± 0.331 fold, p < 0.0002) in patients with preeclampsia compared to control subjects. The miR-26a expression was increased and miR-126 expression was decreased in serum samples of patients with preeclampsia compared to control subjects (p < 0.0002). miR-155 and miR-210 expressions were increased in serum and placental tissue samples of patients with preeclampsia compared to control subjects (p < 0.0002). In conclusion, reduced placental tissue immunostaining of AMH/AMHRII along with increased AMH/AMHRII mRNA expressions may indicate posttranscriptional dysregulation. Robust increase in expressions of hypoxia/inflammation-related miRNAs particularly miR-155 and miR-210 might have a role in this mechanistic pathway. Increased serum levels of miR 26a, 155 and 210 are potential early diagnostic markers for preeclampsia.</p>","PeriodicalId":8970,"journal":{"name":"Biotechnic & Histochemistry","volume":" ","pages":"1-10"},"PeriodicalIF":1.6000,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biotechnic & Histochemistry","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1080/10520295.2024.2389516","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Anti-Mullerian hormone (AMH) has been implicated in the pathogenesis of preeclampsia. The present study was primarily designed to determine the placental tissue AMH, Anti-Mullerian hormone Receptor II (AMHRII), vascular endothelial growth factor (VEGF) and microRNA (miRNA) 26a/126/155/210 expressions and serum miRNA 26a/126/155/210 levels in patients with preeclampsia to examine their potential role in the pathogenesis of preeclampsia. Placental tissue samples from patients with preeclampsia (n = 20) and control subjects (n = 20) were examined by immunohistochemical staining and quantitative polymerase chain reaction (qPCR) for AMH, AMHRII, VEGF mRNA expression levels and miRNA 26a/126/155/210 expressions. Serum levels of miRNA 26a/126/155/210 were measured by qPCR. Patients with preeclampsia had lower AMH/AMHRII immunostaining, particularly in syncytiotrophoblastic cells compared to control subjects (p < 0.05). The relative mRNA expressions of AMH/AMHRII were increased (1.535 ± 0.121 and 1.155 ± 0.049 fold, p < 0.0002 and p < 0.033, respectively) and the relative mRNA expression of VEGF was decreased (4.878 ± 0.331 fold, p < 0.0002) in patients with preeclampsia compared to control subjects. The miR-26a expression was increased and miR-126 expression was decreased in serum samples of patients with preeclampsia compared to control subjects (p < 0.0002). miR-155 and miR-210 expressions were increased in serum and placental tissue samples of patients with preeclampsia compared to control subjects (p < 0.0002). In conclusion, reduced placental tissue immunostaining of AMH/AMHRII along with increased AMH/AMHRII mRNA expressions may indicate posttranscriptional dysregulation. Robust increase in expressions of hypoxia/inflammation-related miRNAs particularly miR-155 and miR-210 might have a role in this mechanistic pathway. Increased serum levels of miR 26a, 155 and 210 are potential early diagnostic markers for preeclampsia.

查看原文本刊更多论文

子痫前期患者胎盘中抗穆勒氏管激素/受体、血管内皮生长因子及相关微RNA的表达：一项病例对照研究。

抗穆勒氏管激素（AMH）与子痫前期的发病机制有关。本研究的主要目的是测定子痫前期患者的胎盘组织AMH、抗穆勒氏管激素受体II（AMHRII）、血管内皮生长因子（VEGF）和microRNA（miRNA）26a/126/155/210的表达以及血清miRNA 26a/126/155/210的水平，以研究它们在子痫前期发病机制中的潜在作用。通过免疫组化染色和定量聚合酶链反应（qPCR）检测子痫前期患者（20 人）和对照组（20 人）的胎盘组织样本中 AMH、AMHRII、VEGF mRNA 的表达水平和 miRNA 26a/126/155/210 的表达。血清中 miRNA 26a/126/155/210 的水平也通过 qPCR 进行了测定。与对照组相比，子痫前期患者的AMH/AMHRII免疫染色较低（p < 0.05），尤其是在合胞滋养细胞中。与对照组相比，子痫前期患者AMH/AMHRII的相对mRNA表达量增加（分别为1.535 ± 0.121和1.155 ± 0.049倍，p < 0.0002和p < 0.033），VEGF的相对mRNA表达量减少（4.878 ± 0.331倍，p < 0.0002）。与对照组相比，子痫前期患者血清样本中 miR-26a 表达增加，miR-126 表达减少（p < 0.0002）。与对照组相比，子痫前期患者血清和胎盘组织样本中 miR-155 和 miR-210 表达增加（p < 0.0002）。总之，胎盘组织中AMH/AMHRII免疫染色的降低和AMH/AMHRII mRNA表达的增加可能表明转录后调节失调。缺氧/炎症相关的 miRNA（尤其是 miR-155 和 miR-210）表达的大量增加可能在这一机制途径中起了作用。血清中 miR 26a、155 和 210 水平的升高可能是子痫前期的早期诊断标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biotechnic & Histochemistry 生物-生物工程与应用微生物

CiteScore

3.40

自引率

6.20%

发文量

审稿时长

6-12 weeks

期刊介绍： Biotechnic & Histochemistry (formerly Stain technology) is the official publication of the Biological Stain Commission. The journal has been in continuous publication since 1926. Biotechnic & Histochemistry is an interdisciplinary journal that embraces all aspects of techniques for visualizing biological processes and entities in cells, tissues and organisms; papers that describe experimental work that employs such investigative methods are appropriate for publication as well. Papers concerning topics as diverse as applications of histochemistry, immunohistochemistry, in situ hybridization, cytochemical probes, autoradiography, light and electron microscopy, tissue culture, in vivo and in vitro studies, image analysis, cytogenetics, automation or computerization of investigative procedures and other investigative approaches are appropriate for publication regardless of their length. Letters to the Editor and review articles concerning topics of special and current interest also are welcome.